Loading...
XNYS
LH
Market cap20bUSD
Jul 11, Last price  
249.62USD
1D
-1.58%
1Q
12.72%
Jan 2017
94.44%
Name

Laboratory Corporation of America Holdings

Chart & Performance

D1W1MN
P/E
28.00
P/S
1.61
EPS
8.92
Div Yield, %
1.15%
Shrs. gr., 5y
-3.11%
Rev. gr., 5y
2.40%
Revenues
13.01b
+6.97%
3,327,600,0003,590,800,0004,068,200,0004,505,200,0004,694,700,0005,003,900,0005,542,300,0005,671,400,0005,808,300,0006,011,600,0008,680,100,0009,641,800,00010,441,400,00011,333,400,00011,554,800,00013,978,500,00016,120,900,00014,876,800,00012,161,600,00013,008,900,000
Net income
746m
+78.47%
386,200,000431,600,000476,800,000464,500,000543,300,000558,200,000519,700,000583,100,000573,800,000511,200,000436,900,000732,100,0001,268,200,000883,700,000823,800,0001,556,100,0002,377,300,0001,279,100,000418,000,000746,000,000
CFO
1.59b
+19.44%
574,200,000632,300,000709,700,000780,900,000862,400,000883,600,000855,600,000841,400,000818,700,000739,000,000982,400,0001,175,900,0001,459,400,0001,305,400,0001,444,700,0002,135,300,0003,109,600,0001,955,900,0001,327,700,0001,585,800,000
Dividend
Aug 29, 20240.72 USD/sh

Profile

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
URL
https://www.labcorp.com/
IPO date
Apr 24, 1991
Employees
60,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
13,008,900
6.97%
12,161,600
-18.25%
14,876,800
-7.72%
Cost of revenue
9,506,800
8,796,700
10,491,700
Unusual Expense (Income)
NOPBT
3,502,100
3,364,900
4,385,100
NOPBT Margin
26.92%
27.67%
29.48%
Operating Taxes
212,400
188,500
302,000
Tax Rate
6.06%
5.60%
6.89%
NOPAT
3,289,700
3,176,400
4,083,100
Net income
746,000
78.47%
418,000
-67.32%
1,279,100
-46.20%
Dividends
(243,100)
(254,000)
(195,200)
Dividend yield
1.26%
1.28%
0.90%
Proceeds from repurchase of equity
(250,100)
(1,000,000)
(1,049,400)
BB yield
1.30%
5.02%
4.87%
Debt
Debt current
1,191,000
1,344,200
492,800
Long-term debt
7,023,100
5,681,900
6,756,900
Deferred revenue
736,200
Other long-term liabilities
517,400
409,300
(294,500)
Net debt
6,679,100
6,462,400
6,754,000
Cash flow
Cash from operating activities
1,585,800
1,327,700
1,955,900
CAPEX
(489,900)
(453,600)
(481,900)
Cash from investing activities
(1,366,800)
(1,171,500)
(1,652,200)
Cash from financing activities
779,900
(59,300)
(1,322,200)
FCF
3,329,900
3,355,000
3,606,900
Balance
Cash
1,518,700
536,800
430,000
Long term investments
16,300
26,900
65,700
Excess cash
884,555
Stockholders' equity
8,063,700
7,852,100
10,115,500
Invested Capital
14,972,145
14,426,200
16,687,100
ROIC
22.38%
20.42%
24.93%
ROCE
21.56%
22.67%
25.17%
EV
Common stock shares outstanding
84,200
87,600
91,600
Price
229.32
0.89%
227.29
-3.48%
235.48
-25.06%
Market cap
19,308,744
-3.02%
19,910,604
-7.69%
21,569,968
-29.59%
EV
26,002,144
26,388,504
28,342,868
EBITDA
4,145,600
3,942,200
5,019,000
EV/EBITDA
6.27
6.69
5.65
Interest
208,300
199,600
180,300
Interest/NOPBT
5.95%
5.93%
4.11%